SmartMedix

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Portland Investment Counsel

Radiomedix, Inc. 

We are excited to share that the Inc Magazine's upcoming issue will feature the life story of Dr. Ebrahim (Abe) S. Delpassand, the CEO of Radio Medix. In the interview, he will discuss his groundbreaking work in radiopharmaceuticals and the future of cancer care. We are excited to offer readers a glimpse into Dr. Delpassand’ s visionary approach.

#RadioMedix #DrEbrahimDelpassand #PET #Cancer #NETcancerday
#Nuclearmedicine #PSMA #PsmaPET

https://lnkd.in/gDr2YFrJ

DelveInsight’s latest Neuroendocrine Tumor pipeline report depicts a robust space, with 55+ active players working to develop 60+ pipeline therapies for Neuroendocrine Tumors treatment. 

Major pharma and biotech giants such as Jiangsu Hengrui Pharmaceuticals Co., Ltd., MedImmune, Genentech, Merck, Pfizer, Takeda, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Inc., Camurus, Pfizer, Radiomedix, Inc. Orano Med, Clarity Pharmaceuticals, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis, Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison, Novatek Pharmaceuticals Ltd., Phanes Therapeutics, Inc., FUJIFILM Pharmaceuticals U.S.A., Inc., Jazz Pharmaceuticals, 23andMe, Celgene, Crinetics Pharmaceuticals, POINT Biopharma, and others are evaluating novel Neuroendocrine Tumors drugs to improve the treatment scenario.

Get a more detailed analysis at: 
https://lnkd.in/dbGeieBJ

#lifesciences #marketresearch #marketanalysis #healthcare #markettrends #health #medical #marketforecast #markettrends #consulting #healthcareconsulting #marketoutlook 

We are excited to share the news that RadioMedix together with business partner, Orano Med, completed patient enrolment in Phase II trial of targeted alpha-emitter therapy using AlphaMedix™ in Neuroendocrine Cancers. This trial is being conducted to evaluate the safety and effectiveness of AlphaMedix™ in peptide receptor radionuclide therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET), regardless of the location of the primary tumor. Top-line data from the trial is expected in mid-2024.
Based on data already collected, the objective response rate (ORR) endpoint has already been achieved and is more than twice as high as the current standard of care.

For more information, please check the press release:
https://lnkd.in/gmqERfnp
#radiomedix, #Pb212, #oranomed, #neuroendocrinetumors, #targetedradiotherapy, #clinicalstudies

RadioMedix, Inc. announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. 225Ac-PSMA-I&T is currently being evaluated under a phase 2 physician-sponsored investigational new drug (IND) under the acronym of TATCIST trial. RadioMedix will also provide manufacturing support to Fusion for the TATCIST trial and first pivotal clinical trial to evaluate the safety and efficacy of 225Ac-PSMA-I&T for metastatic castration-resistant prostate cancer (mCRPC). As currently designed, the trial is expected to evaluate approximately 100 patients with four treatment cycles per patient, occurring every eight weeks. Patients are initially dosed at 100 kBq/kg.#Ac225PSMAI&T #radiopharmaceuticals #TAT

Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative medicines for oncology, including prostate cancer.

Progenics Pharmaceuticals

Endocyte is a biopharmaceutical company that develops targeted therapies for cancer treatment, including radiopharmaceuticals.

Endocyte

Bayer AG is a multinational pharmaceutical and life sciences company with a strong presence in the development of radiopharmaceuticals for cancer diagnosis and treatment.

Bayer AG

RadioMedix, Inc. is a clinical-stage biotechnology company based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company commercializes radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy.

RadioMedix, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 12, 2024 10:28 AM	dd3a433f
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 12, 2024 10:28 AM	c06b40e5
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 12, 2024 10:28 AM	71e59bc7
translate crunchbase fundingrounds	general
peers	general	Feb 12, 2024 10:28 AM	93c53169
news basic	general	Feb 12, 2024 10:28 AM	25e0c103
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:RADIOMEDIX

RadioMedix, Inc.